Revvity, Inc. (RVTY), a life sciences and diagnostics company, on Tuesday revised up its annual guidance.
For fiscal 2026, the company now expects pro forma adjusted earnings of $5.30 to $5.40 per share, compared with the earlier expectation of $5.20 to $5.30 per share. Revvity now anticipates total revenue of $2.83 billion to $2.86 billion, higher than the earlier guidance of $2.81 billion to $2.84 billion.
Prahlad Singh, CEO of Revvity, said: "As we enter the second half of the year, given the clear momentum in our end markets, we are utilizing a portion of recently received tariff refunds to increase investments across the business, capitalize on emerging opportunities, and support future growth."
RVTY was down by 0.62% at $114.49 in the pre-market trade on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.